MG
ANIK icon

Michael Gelband’s Anika Therapeutics ANIK Stock Holding History

Michael Gelband’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,039
Closed -$264K – 1435
2024
Q4 		$264K Buy
+16,039
New +$316K ﹤0.01% 1311
2024
Q2 		– Sell
-15,562
Closed -$395K – 1501
2024
Q1 		$395K Buy
15,562
+29
+0.2% +$702 ﹤0.01% 1193
2023
Q4 		$352K Buy
+15,533
New +$321K ﹤0.01% 1131
2023
Q3 		– Sell
-10,236
Closed -$266K – 1673
2023
Q2 		$266K Buy
+10,236
New +$274K ﹤0.01% 1584
2020
Q4 		– Sell
-8,030
Closed -$284K – 1931
2020
Q3 		$284K Buy
+8,030
New +$290K 0.01% 1317
2020
Q1 		– Sell
-10,725
Closed -$556K – 1061
2019
Q4 		$556K Buy
10,725
+1,557
+17% +$90.4K 0.01% 801
2019
Q3 		$503K Buy
+9,168
New +$471K 0.02% 657

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Michael Gelband's ANIK Position: Q1 2025 in Review

Michael Gelband sold out of Anika Therapeutics (ANIK) in Q1 2025, closing a stake of 16,039 shares — an estimated $264K sold.

Michael Gelband first reported a position in ANIK in Q3 2019 and held it in 7 quarters. The position peaked at $556K in Q4 2019. 108 funds tracked by Wall St. Rank hold ANIK as of Q1 2025.

  • Michael Gelband reported no remaining Anika Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Michael Gelband sold 16,039 Anika Therapeutics shares in Q1 2025, an estimated $264K.
  • Michael Gelband first reported a position in Anika Therapeutics in Q3 2019 and held it in 7 quarters.
  • Michael Gelband's Anika Therapeutics position peaked at $556K in Q4 2019.
  • 108 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2025.

Based on ExodusPoint Capital Management's 13F filing for Q1 2025, filed 14 May 2025.